Introduction
============

Postmastectomy radiotherapy (PMRT) is an important component of breast cancer treatment when microscopic residual disease may be present in the chest wall or regional lymph nodes, despite previous mastectomy and/or adjuvant systemic therapy. Microscopic residual disease can cause locoregional recurrence and distant metastases. Therefore, PMRT is used to eradicate microscopic residual cancer cells and lower the risk of locoregional recurrence and distant metastasis, which enhances survival.

Randomized trials have suggested that PMRT has a beneficial effect on survival, as well as on locoregional recurrence \[[@b1-roj-2018-00458]-[@b3-roj-2018-00458]\]. For patients with ≥4 positive lymph nodes, PMRT is common practice at many institutions. However, the application of these trial data on patients with 1--3 positive nodes remains controversial \[[@b4-roj-2018-00458]\]. Results from the Danish 82B/C trials \[[@b3-roj-2018-00458]\] and the Vancouver British Columbia trial \[[@b2-roj-2018-00458]\] suggested that patients with 1--3 positive lymph nodes benefited from PMRT in terms of locoregional recurrence and prolonged survival. In addition, the newly updated data in the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis from randomized trials demonstrated the benefit of PMRT in these patients \[[@b5-roj-2018-00458]\]. Consequently, the National Comprehensive Cancer Network (NCCN) guidelines \[[@b6-roj-2018-00458]\] strongly recommend PMRT to the ipsilateral chest wall and regional lymphatic area, even in patients with 1--3 positive nodes following mastectomy. However, more recent studies \[[@b7-roj-2018-00458]-[@b10-roj-2018-00458]\] reported a lower locoregional recurrence risk than those from historical trials \[[@b2-roj-2018-00458],[@b3-roj-2018-00458],[@b5-roj-2018-00458]\] for patients with 1--3 positive nodes who were treated with mastectomy and modern adjuvant systemic therapy.

Moreover, PMRT volumes are also controversial. These usually include the ipsilateral chest wall with or without the regional nodal area. However, not all PMRT-indicated patients have the same risk for local and regional recurrence. Additionally, applying chest wall irradiation, regional nodal irradiation, or both could affect treatment efficacy and complications. To design an adequate radiotherapy plan, specific knowledge regarding failure patterns is necessary.

This study aimed to determine the necessity of PMRT and the regions that would be considered at risk for recurrence, by retrospectively evaluating local and regional recurrence risks in patients treated with mastectomy and modern adjuvant systemic treatment.

Materials and Methods
=====================

We performed a retrospective analysis of 436 consecutive patients who had pathologically proven breast cancer with a \<5 cm tumor and 1--3 positive axillary lymph nodes at our institution between 2007 and 2016. This study was approved by Kyungpook National University Chilgok Hospital Institutional Review Board (No. 2018-03-018). Of 436 patients, 205 and 231 were treated with mastectomy and breast-conserving surgery, respectively. From the 205 patients treated with mastectomy, we excluded patients who received neoadjuvant chemotherapy before mastectomy (58 patients), received adjuvant radiotherapy (9 patients), or were followed-up for a short duration (\<3 months) after mastectomy (5 patients). A total of 133 patients were included in the analysis. The expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 was scored based on the CAP/ASCO guidelines \[[@b11-roj-2018-00458],[@b12-roj-2018-00458]\], and each breast cancer was categorized as a molecular subtype based on the expression of these four proteins (luminal A, B, HER2 positive, and basal type), as described in the St. Gallen guidelines \[[@b13-roj-2018-00458]\].

The primary endpoint of this study was to evaluate the risk of local and regional recurrence. The secondary endpoints were to evaluate distant metastasis risk and disease-free survival. Local recurrence was defined as an ipsilateral chest wall recurrence. Regional recurrence was defined as recurrence of the ipsilateral axillary lymph node, internal mammary lymph node, or the supraclavicular lymph node. Distant metastasis was defined as metastasis to distant sites. Disease-free survival was defined as any disease recurrence or any cause of death. All endpoints were calculated from the date of mastectomy and were estimated using the Kaplan-Meier method. Statistical differences were compared using the log-rank test in a univariate analysis. Multivariate analysis using the Cox proportional hazard modeling was performed to identify independent predictors among the prognostic factors. The p-values of \<0.05 were considered statistically significant. All statistical analyses were performed using R statistical software version 3.4.3 (The R Project, <http://www.R-project.org>).

Results
=======

[Table 1](#t1-roj-2018-00458){ref-type="table"} summarizes the patient and tumor-related characteristics. Median age was 49 years (range, 23 to 76 years). Tumor size was ≤2 cm in 56 patients (42.1%) and 2--5 cm in 77 patients (57.9%). Lymphovascular invasion and extracapsular extension were observed in 63 patients (47.4%) and 6 patients (4.5%), respectively. The number of positive lymph nodes were 1, 2, and 3 in 60 patients (45.1%), 52 (39.1%), and 21 (15.8%), respectively. Molecular subtypes were luminal A, B, HER2, and basal type in 64 patients (48.1%), 42 (31.6%), 12 (9.0%), and 15 (11.3%), respectively. Median follow-up period was 57 months (range, 12 to 115 months).

[Table 2](#t2-roj-2018-00458){ref-type="table"} summarizes patient treatment-related characteristics. One-hundred and ten patients (82.7%) were treated with axillary lymph nodes dissection and 23 patients (17.3%) were treated with sentinel lymph node biopsy alone. Adjuvant chemotherapy, endocrine therapy, and trastuzumab therapy were given to 124 patients (93.2%), 112 (84.2%), and 33 (24.8%), respectively. The most common chemotherapy regimen was anthracycline and cyclophosphamide, followed by taxane (95 patients, 71.4%).

1. Local and regional recurrence
--------------------------------

Overall, 3 patients (2.3%) developed local recurrence. Of these, 2 patients had isolated local recurrence and 1 patient had concurrent regional recurrence and distant metastasis with local recurrence. One patient who had an isolated local recurrence later developed distant metastases at 7 months after local recurrence diagnosis. The cumulative 5-year local recurrence rate was 3.1% ([Fig. 1](#f1-roj-2018-00458){ref-type="fig"}). There were no statistically significant clinicopathologic factors associated with local recurrence.

Eight patients (6.0%) experienced regional recurrence ([Table 3](#t3-roj-2018-00458){ref-type="table"}). The median time to regional recurrence was 26 months (range, 5 to 58 months). Seven patients had isolated regional recurrence, and 1 patient was diagnosed with local recurrence and distant metastasis concurrently with regional recurrence. Three patients with regional recurrence later developed distant metastases at 6, 24, and 46 months after the diagnosis of regional recurrence. The cumulative 5-year regional recurrence rate was 8.0%. Among the clinical and pathologic factors, lymphovascular invasion (p = 0.015) was associated with an increased risk of regional recurrence (univariate p = 0.015 and multivariate p = 0.054; hazard ratio (HR) = 7.91; 95% confidence interval (CI), 0.96--64.97) ([Table 4](#t4-roj-2018-00458){ref-type="table"}, [Fig. 2](#f2-roj-2018-00458){ref-type="fig"}). Of note, patients with lymphovascular invasion were at considerable risk for 5-year recurrence (16.1%).

2. Distant metastasis and disease-free survival
-----------------------------------------------

Twelve patients (9.0%) had a distant metastasis. Of these, isolated distant metastasis developed in 7 patients. Median time to distant metastasis was 69.5 months (range, 16 to 115 months). The site of distant metastasis was bone in 6 patients, lung in 4, liver in 1, and liver and bone in 1 patient.

The cumulative 5-year distant metastasis and diseasefree survival rate were 11.7% and 83.4%, respectively. On univariate analysis, factors associated with an increased distant metastasis risk were non-invasive ductal carcinoma (IDC) pathology (p \< 0.001), ER-negative tumor (p = 0.003), and PR-negative tumor (p = 0.034). Among these factors, non-IDC pathology (HR = 1.86; 95% CI, 1.18--2.94; p = 0.008) and estrogen receptor-negative tumor (HR = 0.16; 95% CI, 0.05--0.52; p = 0.003) remained significant in the multivariate analysis.

Regarding disease-free survival, non-IDC pathology (p = 0.002), histologic grade 3 (p = 0.004), ER-negative tumor (p = 0.008), and PR-negative tumor (p = 0.045) were associated with worse outcomes in univariate analysis. Among these factors, non-IDC pathology (HR = 2.91; 95% CI, 1.65--5.14; p \< 0.001) was significantly associated with poorer disease-free survival on multivariate analysis.

Discussion and Conclusion
=========================

In this study, 5-year local and regional recurrence risk were 3.1% and 8.0%, respectively, for breast cancer patients with tumors \<5 cm and 1--3 positive lymph nodes who were treated with mastectomy and modern adjuvant systemic therapy and who did not receive PMRT. Our results are consistent with recent reports that implemented modern systemic therapy \[[@b7-roj-2018-00458]-[@b10-roj-2018-00458]\].

Historical trials have shown higher locoregional recurrence rates in breast cancer patients with 1--3 positive nodes who did not receive PMRT, compared to those reported from modern trials. Specifically, the Danish 82B/C trials \[[@b3-roj-2018-00458]\] showed a 15-year locoregional recurrence risk of 27% and the Vancouver British Columbia trial \[[@b2-roj-2018-00458]\] noted a 20-year isolated locoregional recurrence risk of 21%. PMRT was associated with a significant improvement in both locoregional control and survival for both trials \[[@b2-roj-2018-00458],[@b3-roj-2018-00458]\]. Furthermore, the EBCTCG meta-analysis of data from 22 randomized trials revealed that radiotherapy reduced locoregional recurrence and breast cancer mortality in patients with 1--3 positive nodes \[[@b5-roj-2018-00458]\]. Based on these findings, PMRT was recommended for these patients despite the possibility of radiation-related toxicity.

The standard systemic treatment of breast cancer has recently changed. Most patients in the aforementioned studies were administered adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF regimen); in that era, trastuzumab had not yet been introduced. Anthracycline- and taxane-based chemotherapy has been shown to be more effective than the CMF regimen, and has become the standard adjuvant chemotherapy for node-positive breast cancer patients \[[@b14-roj-2018-00458]-[@b16-roj-2018-00458]\]. In addition, the introduction of trastuzumab and the routine use of tamoxifen or aromatase inhibitors for hormonal receptor-positive disease could further reduce breast cancer recurrence and mortality. Results from the Eastern Cooperative Oncology Group \[[@b17-roj-2018-00458]\] and National Surgical Adjuvant Breast and Bowel Project \[[@b18-roj-2018-00458]\] trials found a locoregional recurrence rate of 13%. Likewise, in a study by McBride et al. \[[@b7-roj-2018-00458]\], the locoregional recurrence rate was lower during the late era than during the early era. Although radiotherapy reduced locoregional recurrence in the early era cohort, it did not benefit patients treated in the later cohort who were also treated with modern systemic treatments. In contrast, a similar study from Korea reported improved disease-free survival in patients treated with PMRT compared to those without radiotherapy during the late era \[[@b19-roj-2018-00458]\]. Additionally, they reported an increased risk of distant metastasis without PMRT in patients in the late era. Accordingly, various studies showed conflicting results regarding the clinical benefit of PMRT in patients with 1--3 positive node in the modern treatment era. Nevertheless, it seems clear that the absolute locoregional recurrence risk has decreased over time in patients treated with modern systemic treatment, and subsequently, the absolute benefit of PMRT is lower when compared with past experience. Similar to other recent studies \[[@b7-roj-2018-00458]-[@b10-roj-2018-00458],[@b20-roj-2018-00458]\], our results showed a respective 5-year local recurrence and regional recurrence risk of 3.1% and 8.0%, which was lower than that of the Danish and British Columbia trials.

The reduced locoregional recurrence risk in node-positive patients led to the attempted selection of high-risk patients for locoregional recurrence, indicated by a sufficient risk of microscopic residual disease \[[@b8-roj-2018-00458],[@b20-roj-2018-00458]-[@b24-roj-2018-00458]\]. Katz et al. \[[@b21-roj-2018-00458]\] suggested that patients with ≥20% of involved nodes or \<20% involved nodes and a tumor size ≥5 cm have significant locoregional recurrence risk and would benefit from PMRT. Lai et al. \[[@b8-roj-2018-00458]\] showed that age ≤40 years, tumor size ≥3 cm, and the presence of extensive intraductal components were risk factors for locoregional recurrence, and a 5-year locoregional recurrence risk of 25% was found in patients with 2 or more risk factors. In a study by Truong et al. \[[@b22-roj-2018-00458]\], age \<45 years, tumor size \>2 cm, histologic grade 3, ER-negative disease, medial tumor location, \>1 positive node, \>25% of nodes being positive were risk factors for recurrence-free survival. Another study analyzed supraclavicular nodal failure in 1--3 node-positive breast cancer patients revealed that lymphovascular invasion, extracapsular extension, the number of involved nodes, and the level of involved nodes were prognostic factors \[[@b23-roj-2018-00458]\]. Similarly, a retrospective multicenter analysis from Korea \[[@b20-roj-2018-00458]\] also found histologic grade 3 as a risk factor for locoregional recurrence. In our study, lymphovascular invasion was a risk factor for regional recurrence, and patients with lymphovascular invasion had a 5-year regional recurrence rate of 16.1%. Taken together, these findings suggest that patients with such poor prognostic factors (e.g., high histologic grade or lymphovascular invasion) might benefit from PMRT to the regional lymphatic area.

Previous studies were primarily concerned about whom to treat, and they did not consider how to treat breast cancer patients with 1--3 positive nodes. PMRT fields usually include the chest wall and regional nodal region (supraclavicular region, infraclavicular region, internal mammary nodes, and any part of the axillary region) \[[@b6-roj-2018-00458]\]. In our study, among the 10 patients with locoregional recurrence, only 3 had chest wall recurrence (2 with isolated chest wall recurrence and 1 with both chest wall and lymph node recurrence). The cumulative 5-year local recurrence risk was only 3.1%. Failure patterns found in a study of Lai et al. \[[@b8-roj-2018-00458]\] were similar to our results, in that they noted that regional recurrence was a more frequent failure pattern in breast cancer patients with 1--3 positive nodes who were treated with mastectomy and adjuvant systemic treatment. Likewise, a Korean multicenter study (KROG 14--18) also reported that the frequency of local recurrence (6/584 patients) had an incidence of approximately 1/4 for regional recurrence (22/584 patients) \[[@b20-roj-2018-00458]\]. Other recently published results from two Korean multicenter studies (KROG 14--22 and KROG 14--23) showed very low chest wall recurrence rate in patients with \<5 cm tumor and 1--3 positive lymph nodes \[[@b25-roj-2018-00458]\]. Based on these results, the authors questioned the necessity of chest wall radiotherapy in this group of patients.

Various complications may occur following chest wall irradiation. Frequent symptoms include chest wall pain, acute dermatitis, and late skin fibrosis. In addition, for left-sided breast cancer patients, an increase in cardiac-related mortality has been observed \[[@b26-roj-2018-00458],[@b27-roj-2018-00458]\]. Specifically, Darby et al. \[[@b28-roj-2018-00458]\] reported that the rate of major coronary events increased linearly with the heart mean dose by 7.4% per Gy. Furthermore, high rates of late contraction, fibrosis, capsular contracture, reconstructive failure, and poor cosmetic outcome were reported for patients who received immediate breast reconstruction followed by PMRT. Complications of reconstructed breast more frequently occur for patients who had implant reconstruction, compared with those that had autologous reconstruction \[[@b10-roj-2018-00458],[@b29-roj-2018-00458]\]. In a recent prospective study on breast reconstruction by the Mastectomy Reconstruction Outcomes Consortium (MROC), PMRT was associated with an increased risk of complications at 2 years for patients who had an implant reconstruction, while PMRT had similar risks in patients who received autologous reconstruction \[[@b30-roj-2018-00458]\]. Given the rising expectations of cosmetic outcomes in breast cancer patients in the contemporary era, PMRT needs to be more sophisticated and tailored. In this context, the local recurrence risk might need to be considered separately from the regional recurrence risk. The low risk of local recurrence shown in our study and in other studies suggests the possibility of irradiating the regional nodal area and omitting the chest wall for patients who have a high risk for regional recurrence ([Fig. 3](#f3-roj-2018-00458){ref-type="fig"}). In doing so, complications related to chest wall irradiation could be alleviated. However, the current known risk factors from most previous studies concerned locoregional recurrence as a single entity. Hence, to safely omit chest wall irradiation from PMRT for patients with a high risk of regional recurrence, further data should be collected.

Our study has some limitations. First, there may be unknown selection bias due to the retrospective design. In particular, many patients were treated with neoadjuvant chemotherapy since 2008 and there is a possibility that we included low-risk, node-positive patients. Second, the total number of patients and the number of recurrence events may be too small to ensure statistical relevance of our results. Third, a relatively short follow-up period also limits our study findings. Nevertheless, our results provide information regarding local and regional recurrence separately, which may be used to support radiotherapy that is tailored according to whether risk of recurrence is local or regional. Our results warrant further investigation in future trials.

In conclusion, our study showed a very low 5-year local recurrence rate of 3.1% in breast cancer patients with a tumor size of \<5 cm and 1--3 positive nodes who were treated with mastectomy and modern adjuvant systemic treatment without radiotherapy. No significant risk factors associated with increased local recurrence were found. The PMRT volume need to be tailored for each patient's given risk for local and regional recurrence, considering the possible toxicities and benefits of chest wall irradiation.
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![Kaplan-Meier curves for local recurrence (A), regional recurrence (B), distant metastasis (C), and disease-free survival (D) for all 133 study patients.](roj-2018-00458f1){#f1-roj-2018-00458}

![Kaplan-Meier curves for regional recurrence for patients with lymphovascular invasion (LVI, dashed red line) and without LVI (blue line).](roj-2018-00458f2){#f2-roj-2018-00458}

![Postmastectomy radiotherapy treatment plans for a 53-year-old female with breast cancer who underwent mastectomy, sentinel node biopsy, and immediate implant reconstruction. Radiotherapy volume included the ipsilateral chest wall, axillary, and supraclavicular region (A); while only the axillary and supraclavicular region without covering the ipsilateral chest wall (B).](roj-2018-00458f3){#f3-roj-2018-00458}

###### 

Patient and tumor characteristics (n = 133)

  Characteristic                                                                  Value
  ------------------------------------------------------------------------------- -------------
  Age (yr)                                                                        49 (23--76)
   ≤40                                                                            25 (18.8)
   \>40                                                                           108 (81.2)
  Pathology                                                                       
   Invasive ductal carcinoma                                                      119 (89.5)
   Invasive lobular carcinoma                                                     11 (8.3)
   Others                                                                         3 (2.3)
  Tumor size                                                                      
   ≤2 cm                                                                          56 (42.1)
   \>2 cm                                                                         77 (57.9)
  Histologic grade                                                                
   1                                                                              18 (13.5)
   2                                                                              81 (60.9)
   3                                                                              34 (25.6)
  Nuclear grade                                                                   
   1                                                                              6 (4.5)
   2                                                                              60 (45.1)
   3                                                                              65 (48.9)
   Unknown                                                                        2 (1.5)
  Multiplicity                                                                    
   Yes                                                                            40 (30.1)
   No                                                                             93 (69.9)
  Estrogen receptor status^[a)](#tfn1-roj-2018-00458){ref-type="table-fn"}^       
   Positive                                                                       105 (78.9)
   Negative                                                                       28 (21.1)
  Progesterone receptor status^[a)](#tfn1-roj-2018-00458){ref-type="table-fn"}^   
   Positive                                                                       87 (65.4)
   Negative                                                                       46 (34.6)
  HER2 status                                                                     
   Positive^[b)](#tfn2-roj-2018-00458){ref-type="table-fn"}^                      35 (26.3)
   Negative                                                                       98 (73.7)
  Ki-67                                                                           
   \<14%                                                                          66 (49.6)
   ≥14%                                                                           53 (39.8)
   Unknown                                                                        14 (10.5)
  Molecular subtype                                                               
   Luminal A                                                                      64 (48.1)
   Luminal B                                                                      42 (31.6)
   HER2                                                                           12 (9.0)
   Basal                                                                          15 (11.3)
  Lymphovascular invasion                                                         
   Present                                                                        63 (47.4)
   None                                                                           69 (51.9)
   Unknown                                                                        1 (0.8)
  Extracapsular extension                                                         
   Present                                                                        6 (4.5)
   None                                                                           126 (94.7)
   Unknown                                                                        1 (0.8)
  No. of positive lymph nodes                                                     
   1                                                                              60 (45.1)
   2                                                                              52 (39.1)
   3                                                                              21 (15.8)
  No. of dissected lymph nodes                                                    
   \<10                                                                           38 (28.6)
   ≥10                                                                            95 (71.4)

Values are presented as median (range) or number (%).

Determined by immunohistochemical stain of estrogen receptor and progesterone receptor.

Determined by immunohistochemical stain (3+) or silver in situ hybridization (+).

###### 

Treatment characteristics (n =133)

  Characteristic                    No. of patients (%)
  --------------------------------- ---------------------
  Types of axillary management      
   Axillary lymph node dissection   110 (82.7)
   Sentinel lymph node biopsy       23 (17.3)
  Chemotherapy                      
   AC followed by T                 95 (71.4)
   AC                               9 (6.8)
   CMF                              10 (7.5)
   TC                               7 (5.3)
   Other                            3 (2.3)
   No                               9 (6.8)
  Anti-hormonal therapy             
   Tamoxifen                        75 (56.4)
   Aromatase inhibitor              37 (27.8)
   No                               21 (15.8)
  Trastuzumab                       
   Yes                              33 (24.8)
   No                               100 (75.2)

AC, adriamycin and cyclophosphamide; T, taxane; CMF, cyclophosphamide, methotrexate, and fluorouracil; TC, taxane and cyclophosphamide.

###### 

Details of local and regional recurrences

  Case no.   Age (yr)   Resection margin   Positive nodes/Removed nodes   LVI   ECE   Molecular subtype   Histologic grade   Tumor size (mm)   Time to recurrence (mo)   Site of recurrence     Concurrent distant metastasis
  ---------- ---------- ------------------ ------------------------------ ----- ----- ------------------- ------------------ ----------------- ------------------------- ---------------------- -------------------------------
  1          38         Close (\<1 mm)     3/24                           Yes   No    TN                  3                  24                7                         Chest wall             No
  2          41         Negative           1/2                            Yes   No    Luminal B           3                  18                35                        Chest wall             No
  3          50         Negative           1/3                            Yes   No    Luminal B           2                  25                56                        Chest wall, IMN, SCN   Yes
  4          23         Negative           1/9                            Yes   No    Luminal B           2                  46                6                         IMN                    No
  5          37         Positive           1/15                           No    Yes   Luminal B           2                  12                14                        SCN                    No
  6          49         Positive           2/14                           Yes   No    Luminal A           1                  27                38                        Level 1 axilla, SCN    No
  7          63         Positive           1/19                           Yes   No    TN                  3                  19                58                        IMN                    No
  8          44         Negative           1/7                            Yes   No    Luminal B           3                  7                 11                        Level 1 axilla         No
  9          60         Negative           2/22                           Yes   No    TN                  3                  34                5                         IMN                    No
  10         46         Negative           1/12                           Yes   No    Luminal A           3                  33                40                        Rotter's node          No

LVI, lymphovascular invasion; ECE, extracapsular extension; TN, triple-negative; IMN, internal mammary node; SCN, supraclavicular node.

###### 

Regional recurrence with respect to clinicopathologic factors

                                                                     5-yr risk of regional recurrence (%)   p-value   
  ------------------------------------------------------------------ -------------------------------------- --------- ---------------------------
  Age (yr)                                                                                                  0.691     
   ≤40                                                               8.0                                              
   \>40                                                              8.2                                              
  Pathology                                                                                                 0.796     
   IDC                                                               8.1                                              
   Non-IDC                                                           7.1                                              
  Tumor size (cm)                                                                                           0.840     
   ≤2                                                                7.8                                              
   \>2                                                               8.3                                              
  Histologic grade                                                                                          0.098     0.332 (1.80, 0.55--5.89)
   1--2                                                              5.3                                              
   3                                                                 16.0                                             
  Nuclear grade                                                                                             0.513     
   1--2                                                              0.0                                              
   3                                                                 8.6                                              
  Multiple                                                                                                  0.153     
   Yes                                                               15.2                                             
   No                                                                5.4                                              
  Estrogen receptor                                                                                         0.848     
   Positive                                                          7.3                                              
   Negative                                                          10.0                                             
  Progesterone receptor                                                                                     0.981     
   Positive                                                          8.0                                              
   Negative                                                          8.0                                              
  HER2                                                                                                      0.279     
   Positive                                                          2.9                                              
   Negative                                                          10.7                                             
  Ki-67 (%)                                                                                                 0.166     
   \<14                                                              4.1                                              
   ≥14                                                               10.9                                             
  Molecular subtype                                                                                         0.247     
   Luminal A                                                         4.3                                              
   Non-luminal A                                                     10.6                                             
  Lymphovascular invasion                                                                                   0.015     0.054 (7.91, 0.96--64.97)
   Yes                                                               16.1                                             
   No                                                                1.5                                              
  Extracapsular extension                                                                                   0.236     
   Yes                                                               16.7                                             
   No                                                                7.7                                              
  Positive lymph node                                                                                       0.078     
   1                                                                 14.3                                             
   ≥2                                                                3.1                                    0.250     
  Nodal ratio^[a)](#tfn3-roj-2018-00458){ref-type="table-fn"}^ (%)                                                    
   \<20                                                              9.4                                              
   ≥20                                                               4.5                                              

IDC, invasive ductal carcinoma; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; CI, confidence interval.

Ratio of positive lymph nodes of the total dissected lymph nodes.
